chronic%20lymphocytic%20leukemia
CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.

 

Chronic Lymphocytic Leukemia Drug Information

Drug Information

Indication: Agammaglobulinemia/hypogammaglobulinemia. Combined therapy w/ antibiotics in severe bacterial or viral infecti...

Indication: Adult patients w/ relapsed or refractory mantle cell lymphoma (MCL), previously untreated chronic lymphocytic ...

Indication: Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has pro...

Indication: Adjuvant of maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylitis...

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

Indication: Primary humoral immunodeficiency. Idiopathic thrombocytopenic purpura. Chronic inflammatory demyelinating poly...

Indication: In combination w/ chemotherapy, followed by maintenance therapy in patients achieving a response for previousl...

Indication: Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, Waldenstrom's macro...

Indication: Relapsed or chemoresistant low-grade or follicular, CD20 +ve, B-cell non-Hodgkin's lymphoma (NHL); previously ...

Indication: Relapsed or chemoresistant low-grade or follicular, CD20 +ve, B-cell non-Hodgkin's lymphoma (NHL); previously ...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
16 Sep 2020
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.